Publication
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (5)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 5
- cancerAcute Myeloid Leukemiacivic_curation1.00
- drugQuizartinibcivic_curation1.00
- drugSorafenibcivic_curation1.00
- geneFLT3civic_curation1.00
- variantFLT3 D835civic_curation1.00
Curated evidence
Evidence citing this paper (4)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 22504184
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| FLT3 D8351 | ||||||||
| Quizartinib + SorafenibSubstitutes | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | B | Supports Resistance | 4 | accepted | EID1038In an in-vitro study using an in vitro saturation mutagenesis assay, 4 residues with AC220 (quizartinib) resistance-conferring mutations in the kinase domain of FLT3-ITD were identified. Mutations at … (full text at CIViC) PMID 22504184 · Smith et al., 2012 · Open in CIViC | civic |
| FLT3 F691L1 | ||||||||
| Quizartinib | Acute Myeloid LeukemiaCURATED_BROADER | Predictive | B | Supports Resistance | 3 | submitted | EID9718Using AC220 (Quizartinib) treatment in Ba/F3 cell lines in a in vitro saturation mutagenesis assay, variants in four residues in FLT3 kinase domain were found, including E608, F691, D835 and Y842. Exc… (full text at CIViC) PMID 22504184 · Smith et al., 2012 · Open in CIViC | civic |
| FLT3 D835V + FLT3 D835Y + FLT3 F691L + FLT3 ITD + FLT3 Y842C + FLT3 Y842H1 | ||||||||
| Sorafenib | Malignant NeoplasmALIAS | Predictive | D | Supports Resistance | 3 | submitted | EID12629In an in-vitro study using an in vitro saturation mutagenesis assay, residues with AC220 (quizartinib) resistance-conferring mutations in the kinase domain of FLT3-ITD were identified. These mutations… (full text at CIViC) PMID 22504184 · Smith et al., 2012 · Open in CIViC | civic |
| FLT3 ITD + FLT3 Y842C + FLT3 Y842H1 | ||||||||
| Quizartinib | Malignant NeoplasmALIAS | Predictive | D | Supports Resistance | 3 | submitted | EID12628In an in-vitro study using an in vitro saturation mutagenesis assay, residues with AC220 (quizartinib) resistance-conferring mutations in the kinase domain of FLT3-ITD were identified, including Y842C… (full text at CIViC) PMID 22504184 · Smith et al., 2012 · Open in CIViC | civic |